Updated daily
Drug recalls
Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.
Class IIITerminatedJul 1, 2020R.E.C.KPresence of Particulate Matter: Fresenius Kabi recalling vials of KetorolacQuVa Pharma, Inc. · D-1335-2020Class IITerminatedJul 1, 2020Metformin Hydrochloride Extended-release Tablets USPCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelLupin Pharmaceuticals Inc. · D-1334-2020Class IITerminatedJul 1, 2020metFORMIN HCL ER 500 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelPD-Rx Pharmaceuticals, Inc. · D-1333-2020Class IITerminatedJul 1, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelTeva Pharmaceuticals USA · D-1332-2020Class IITerminatedJul 1, 2020Metformin Hydrochloride Extended - Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelTeva Pharmaceuticals USA · D-1331-2020Class IITerminatedJul 1, 2020Sterile Curcumin 50mg/mLLack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and CurcuminBIOTA Biosciences LLC · D-1330-2020Class IITerminatedJul 1, 2020Sterile CannabidiolLack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and CurcuminBIOTA Biosciences LLC · D-1329-2020Class IITerminatedJul 1, 2020Sterile CannabidiolLack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and CurcuminBIOTA Biosciences LLC · D-1328-2020Class IITerminatedJul 1, 2020Sterile CurcuminLack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and CurcuminBIOTA Biosciences LLC · D-1327-2020Class IITerminatedJul 1, 2020Sterile CannabidiolLack of Assurance of Sterility and Marketed without an approved NDA/ANDA: Product contains unapproved Cannabidiol and CurcuminBIOTA Biosciences LLC · D-1326-2020Class IITerminatedJun 24, 2020Gaviscon Liquid Antacid Extra StrengthLabeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.Glaxosmithkline Consumer Healthcare Holdings · D-1325-2020Class IITerminatedJun 24, 2020Gaviscon Extra Strength Liquid Antacid Extra Strength CherryLabeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.Glaxosmithkline Consumer Healthcare Holdings · D-1324-2020Class IITerminatedJun 24, 2020Gaviscon Regular Strength Liquid Antacid Cool MintLabeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.Glaxosmithkline Consumer Healthcare Holdings · D-1323-2020Class IITerminatedJun 24, 2020Gaviscon Regular Strength Liquid Antacid Cool MintLabeling: Label lacks warning - Magnesium safety warning is not present on the Gaviscon bottle label.Glaxosmithkline Consumer Healthcare Holdings · D-1322-2020Class IIITerminatedJun 24, 2020Olanzapine TabletsFailed Impurities/ Degradation SpecificationsAurobindo Pharma USA Inc. · D-1315-2020Class IIITerminatedJun 24, 2020Olanzapine TabletsFailed Impurities/ Degradation SpecificationsAurobindo Pharma USA Inc. · D-1314-2020Class IITerminatedJun 24, 2020Heparin Sodium 5Subpotent Drug: Out-of-Specification potency results at the 30-day stability timepoint.SCA Pharmaceuticals · D-1311-2020Class IITerminatedJun 24, 2020EcoLips Sport Lip BalmSuperpotent Drug: The active ingredient, avobenzone, is used at 5% which is higher than the allowable 3% in the sunscreen formula per FDA sunscreen regulations.Eco Lips Inc · D-1310-2020Class IITerminatedJun 24, 2020Irinotecan HCL InjectionDefective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.Hikma Pharmaceuticals USA Inc. · D-1309-2020Class IITerminatedJun 24, 2020Irinotecan HCL InjectionDefective Container: Customer complaints received of a crimp defect while removing the flip-cap during use.Hikma Pharmaceuticals USA Inc. · D-1308-2020Class IITerminatedJun 24, 2020metFORMIN HCL ER USP 500 mgCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelPD-Rx Pharmaceuticals, Inc. · D-1307-2020Class IITerminatedJun 24, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAVKARE Inc. · D-1305-2020Class IITerminatedJun 24, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above the acceptable intake levelAVKARE Inc. · D-1304-2020Class IICompletedJun 24, 2020Metformin Hydrochloride Extended-Release TabletsCGMP Deviations: FDA analysis detected N-Nitrosodimethylamine (NDMA) impurity above acceptable intake levelsApotex Inc. · D-1303-2020Class IIITerminatedJun 17, 2020Prednisolone Sodium Phosphate Oral SolutionDiscoloration: Out of Specification (OOS) result for APHA Color Test.Akorn, Inc. · D-1340-2020Class IITerminatedJun 17, 2020Unasyn (ampicillin sodium/sulbacatam) for injectionPresence of Particulate Matter: particulate matter identified after reconstitution.Pfizer Inc. · D-1306-2020Class IITerminatedJun 17, 2020oxyTOCIN 30 Units/500 mLSubpotent drug - Product did not contain drug.QuVa Pharma, Inc. · D-1302-2020Class IITerminatedJun 17, 2020Ketorolac Tromethamine InjectionPresence of Particulate Matter - found in reserve sample vials at the firm.Fresenius Kabi USA, LLC · D-1297-2020Class ITerminatedJun 17, 2020Ketorolac Tromethamine InjectionPresence of Particulate Matter - found in reserve sample vials at the firm.Fresenius Kabi USA, LLC · D-1296-2020Class IITerminatedJun 17, 2020Doxycycline Hyclate TabletsFailed dissolution specification - dissolution results of 59% (spec. NLT 85%) at the 24 month time point (end of shelf life).American Health Packaging · D-1293-2020Class IIITerminatedJun 17, 2020Clonidine Hydrochloride TabletsFailed Impurities/Degradation Specifications: potential migration of benzophenone at very low level into the product from container.Unichem Pharmaceuticals USA Inc · D-1291-2020Class IITerminatedJun 17, 2020Lisinopril TabletsProduct Mix Up: Lisinopril 10 mg tablets were found in Lisinopril 5 mg 1000-count bottle.Lupin Pharmaceuticals Inc. · D-1290-2020Class IITerminatedJun 10, 2020Carbamazepine TabletsFailed Dissolution SpecificationsTorrent Pharma Inc. · D-1317-2020Class ITerminatedJun 10, 2020NP Thyroid 90Superpotent Drug.Acella Pharmaceuticals, LLC · D-1300-2020Class ITerminatedJun 10, 2020NP Thyroid 60Superpotent Drug.Acella Pharmaceuticals, LLC · D-1299-2020Class ITerminatedJun 10, 2020NP Thyroid 30Superpotent Drug.Acella Pharmaceuticals, LLC · D-1298-2020Class IIITerminatedJun 10, 2020Lamotrigine TabletsPresence of Foreign Substance consistent with granules from desiccant packs used during storageAVKARE Inc. · D-1289-2020Class IITerminatedJun 10, 2020Doxycycline Hyclate TabletsFailed Dissolution Specification: The dissolution test at the 24 month time point (end of shelf life) yielded an out-of-specification result.The Harvard Drug Group · D-1288-2020Class IITerminatedJun 10, 2020Dextroamphetamine SaccharateSome bottles may contain mixed strengths of the product.Teva Pharmaceuticals USA · D-1287-2020Class IITerminatedJun 10, 2020Dextroamphetamine SaccharateSome bottles may contain mixed strengths of the product.Teva Pharmaceuticals USA · D-1286-2020